Eli Lilly and Company enters the final days of May having added 4.2% on the week, closing at $1,064.74 — its highest level since early in the year — with a fresh analyst target raise from BofA arriving the same day to frame the move.
The Street action is the week's standout. BofA's Jason Gerberry raised his price target to $1,251 from $1,133 on May 26 while reiterating Buy — a 10.4% lift to his target, filed the same session the stock closed near its weekly high. That follows Barclays lifting its target to $1,400 from $1,350 on May 5, and Cantor Fitzgerald nudging to $1,230 shortly after Q1 results. The direction of travel is uniformly constructive: every recent change in the analyst file has maintained a Buy or Outperform rating, and the mean price target now stands at $1,215. That implies roughly 14% upside from current levels — a gap that has tightened meaningfully as the stock has recovered, but still leaves room for the bullish thesis to play out. The bear case on the Street centres on GLP-1 pricing pressure and pipeline execution risk; bulls lean on the breadth of the therapeutic portfolio and strong forward EPS momentum, which ranks in the 78th percentile on both 30-day and 90-day windows.
Positioning is notably relaxed given the size of the move. Short interest has continued the pullback flagged in last week's note. After the May 15 spike to 9.2 million shares, the figure has retreated steadily to 7.64 million — around 0.85% of the free float — a level that offers no meaningful squeeze dynamic. Borrowing costs are barely worth discussing at 0.50%, and the lending pool is essentially unconstrained, with availability well into the thousands of percent. None of that points to a market placing a structural short bet against Lilly; the low short score of 29.8 confirms it.
Options positioning has eased slightly from the elevated levels that defined the past two weeks. The put/call ratio is running at 1.13, still above its 20-day average of 1.08 but with a z-score of just 0.71 — a much more neutral read than the two-standard-deviation skew seen on May 20. The 52-week range on PCR runs from 0.51 to 1.37, so the current level is in the upper half but nowhere near the defensive extreme. Taken together with the low short interest, this points to a market that has hedged incrementally into the rally rather than one braced for a sharp reversal.
The Q1 print on April 30 delivered a 13.2% one-day jump and held most of it over the subsequent five days, ending the week up 14.5%. That reaction materially reset sentiment. The stock had traded well below $1,000 through much of April; it is now 20% higher than a month ago. Institutional ownership remains anchored by the Lilly Endowment at just over 10%, with BlackRock, Vanguard, and Capital Research all adding modestly in their most recent filings. The only insider sales on record are routine compensation-related transactions, all of insignificant size relative to the company.
Among peers, MRK gained 6.4% on the week while BMY added 1.3% — both posting positive moves, but well short of LLY's weekly pace. The next catalyst on the calendar is the August 5 Q2 earnings report; between now and then, GLP-1 pricing headlines and any pipeline-related FDA communications are the data points most likely to test how durable this recovery is.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
